Re-posted from PR Newswire
PANTHERx® Specialty Pharmacy has been recognized as the winner of the Specialty Pharmacy Patient Choice Awards™ for the non-PBM/payer category presented during the 2017 Asembia Specialty Pharmacy Summit in Las Vegas, Nevada. “We are honored to receive this award as the top specialty pharmacy in overall patient satisfaction for 2016,” says PANTHERx Specialty Pharmacy CEO, Dr. Gordon Vanscoy. “No other measure and recognition could mean more to us. We are humbled to be recognized in a field of finalists which represent many of the best specialty pharmacies in the United States. Our involvement in the Zitter Health Patient Satisfaction Surveys has afforded us validation that our mission to redefine the level of care provided in specialty pharmacy is being recognized by the patients whom we serve on a daily basis. Valid independent patient satisfaction survey benchmarking, regardless of source, raises the quality bar for the industry. Most importantly, the patient wins.”
This announcement comes on the heels of PANTHERx’s recognition as the top overall Specialty Pharmacy in Patient Satisfaction for the past two consecutive quarters in the Zitter Health Insights Patient Satisfaction Survey, which assesses all specialty pharmacies in the U.S. “Our approach to patient engagement is highly focused on sustained relationship-building and finding unrivaled ways to do so,” says Dr. Douglas Gebhard, VP of Quality & Education at PANTHERx. “We continually challenge ourselves to disrupt and innovate new ways to connect with patients so they understand they are not just a number to us. Our teams live our Mission, Vision, and Values so that they can follow a consistent patient-centric culture, the PANTHERx way of taking care of patients.”
About the Award
The Specialty Pharmacy Patient Choice Award was created by Zitter Health Insights and Specialty Pharmacy Times to honor specialty pharmacies and their commitment to patients. The criteria for the award were formulated by an external awards committee made up of prominent individuals representing pharmaceutical manufacturers, payers, trade organizations, consultants, and equity research firms. Pharmacies were selected for a Patient Choice Award based on their average Net Promoter Score (NPS) from all four quarterly surveys conducted during the 2016 calendar year. PANTHERx Specialty Pharmacy’s average NPS across all categories for 2016 was 94. This score was the highest average NPS across all 38 specialty pharmacies assessed during the 2016 calendar year.
About the Survey
The Zitter Health Insights survey assesses numerous aspects of patient satisfaction and analyzes responses from more than 10,000 specialty pharmacy patients across all specialty pharmacies every year. By leveraging an independent entity to aggregate unbiased patient feedback, specialty pharmacies can objectively assess how they are perceived by their patients, as well as benchmark how they compare to competitor performance in the areas of patient perception, access, and adherence. The NPS – an index of -100 to 100 that measures patients’ willingness to recommend their pharmacy to others, is the overall key measure of the survey. The highest score ever achieved by any specialty pharmacy surveyed by Zitter Health Insights was recorded by PANTHERx in Q3 2016 when they received an NPS of 98.
About PANTHERx Specialty Pharmacy
PANTHERx® Specialty Pharmacy is THE Rare Disease Specialty Pharmacy®, servicing patients nationwide, and is headquartered in Pittsburgh, Pennsylvania. PANTHERx’s mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. PANTHERx was recently recognized as the fastest growing healthcare company by Inc magazine and in the top 5 places to work by Modern Healthcare. PANTHERx identifies opportunities every day to Reinvent Specialty, Revolutionize Pharmacy, and Redefine Care, by developing focused solutions, bold innovation, and novel clinical services associated with the life-transforming therapies.